Gastrointestinal (GI) infections continue to significantly contribute to global health burden, causing an array of illnesses from acute gastroenteritis to life-threatening colitis and precipitating healthcare-associated outbreaks. These diseases maintain a high global morbidity ranking with billions of incidents reported annually. The response to these infections remains inconsistent as the risk and outcomes are defined by factors such as access to clean water, sanitation, nutrition, healthcare infrastructure, and the presence of immunosuppression and comorbid conditions. Increasing rates of antimicrobial resistance (AMR) further complicate the treatment of these pathogens.
The landscape of GI infections has seen continuous flux. The introduction of vaccines against Rotavirus, a primary cause of severe childhood diarrhea, has effectively lowered mortality rates. Norovirus has earned recognition as the leading cause of acute gastroenteritis and a potent instigator of outbreaks in community and healthcare environments. In wealthy regions, Clostridioides difficile infection (CDI) presents a formidable challenge in modern infection prevention due to its high incidence and severe outcomes.
The role of the Gastrointestinal Infection section of Frontiers in Gastroenterology is to facilitate advancements across varied areas such as epidemiology, diagnostics, therapeutics, infection prevention, antimicrobial stewardship, and the microbiome. It brings attention to critical research issues and the necessary practices for the next decade while emphasizing the importance of translating these into the achievement of equitably distributed impact.
Understanding the effect of socio-demographic conditions on disease etiology is crucial. Lower-resource settings typically grapple with illnesses such as rotavirus and cryptosporidiosis, while CDI is more prominent in high socio-demographic index (SDI) regions. The challenges in these areas differ, with wealthy regions dealing with incidence complexity due to advanced treatments and prolonged care stages that provide an opportunity for severe disease and pathogenic spread within healthcare networks.
Conversely, lower-resource regions face a persistent combination of enteric pathogens, undernutrition, limited diagnostic access, late care, and deficits in sanitation and hygiene, which amplifies disease incidence and severity. The adoption of culture-independent diagnostic tests (CIDTs) and multiplex gastrointestinal panels has revolutionized surveillance and perceived incidence for several pathogens.
As technological advancements promise shorter diagnostic times and earlier treatment optimization, they also introduce new problems. For example, the BioFire FilmArray GI panel can promptly identify pathogens but often generates co-detections, creating interpretation difficulties. Additionally, without quantitative outputs, distinguishing causation from coincidence becomes a challenge leading to potential over and under-treatment.
The promising field of multiplex PCR panels demands further advancements including faster and more detailed surveillance integrating clinical data, laboratory analytics, genomics, and environmental signals, all while maintaining privacy and facilitating rapid public health action.
In the management of acute infectious diarrhea, hydration and electrolyte replacement remain critical. However, when antibiotics are indicated, the choices are increasingly constrained by resistance and collateral harms such as selection for multidrug-resistant organisms, microbiome disruption, and increased CDI risk. Challenges in implementing susceptibility-guided therapy at scale include access to molecular resistance testing, validation of point-of-care sampling approaches, evaluation of novel antibiotics, and outcome-based strategies.
Prevention remains the most effective strategy for reducing the burden of GI infections. This prevention includes the institution of clean water, sanitation, hygiene, safe food systems, and vaccination. On the frontier of prevention, research is ongoing into the creation of vaccines for pathogens like the norovirus.
The battle against the increasing influence of antimicrobial resistance (AMR) remains a grand challenge as it has become a massive contributor to mortality and healthcare strain. GI infections interlink community transmission, food systems, and healthcare exposures, thus serving as both an indicator and spreader of resistance. The World Health Organization’s listing of priority pathogens underlines several enteric organisms of high concern, directly mapping onto clinical challenges in dysentery, enteric fever, and healthcare-associated diarrhea. The future holds a promise of addressing these and further challenges with the continued development of scientific understanding and healthcare technology.
Source: https://www.frontiersin.org/journals/gastroenterology/articles/10.3389/fgstr.2026.1808344/full